Previous findings suggest that plasma NfL increases in response to amyloid-related neuronal injury in preclinical stages of Alzheimer’s disease, but is related to tau-mediated neurodegeneration in symptomatic patients [22]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.